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Current recommendations, particularly those related to intracranial pressure (ICP), 1 remain controversial owing to the questions raised by single-center studies and international trials about the benefit 2-4 and feasibility 5 of implementation. Based on a national assessment of US trauma medical directors (TMDs), the objective of our study was to determine the extent to which BTF guidelines are used.
Methods | Our study was conducted as part of a larger project assessing the military-to-civilian translation of battlefield innovations in surgical trauma care, the methods of which have been previously described. 6 The TMDs provided written informed consent and completed an anonymous, uncompensated electronic survey designed to collected data on trauma center demographics and on use of BTF guidelines. The survey was designed using a modified Delphi technique involving multiple consultations with an expert physician/surgeon panel. Pilot testing was conducted among a group of 12 trauma-section chiefs. Descriptive statistics compared differences in trauma center level (levels I-III).
The institutional review board of the Johns Hopkins University School of Medicine approved our study. O u r f i n d i ng s a s s e s s i ng t h e e x t e nt o f p o l i c i e s reflecting the use of BTF guidelines among US trauma centers point to a similar trend. While the majority of TMDs reported institutional policies and perceived use consistent with overall use of BTF guidelines, use of more specific contentious recommendations, such as ICP monitoring, varied. Of 245 TMDs, 150 (61.2%) stated that ICP policies were implemented in less than 60% of STBI cases. Study limitations, including the potentially subjective nature of the TMDs' reports, need to be taken into account.
Estimation of Life-Years Saved by Solid-Organ Transplant
To the Editor Using data collected over 25 years from the United Network for Organ Sharing database, Rana and colleagues result of transplant using the time of transplant listing, patients receiving a transplant are required to survive until they receive the transplant, making them "immortal" for the entire time they spend on the waiting list; this contrasts with waiting list-only patients, who, by definition, can die at any time following initial listing prior to transplant. Therefore, with this approach, the survival time accrued between the time of listing and the time of transplant for patients who received a transplant is misclassified as survival that is due to the transplant. As a result, the benefit of a transplant is overstated. While, given prior studies, 2,4,5 we are confident that a transplant has advantages over dialysis for most patients, the results provided by Rana and colleagues 1 are fatally biased and therefore
should not be used in clinical practice to frame the potential benefits of solid-organ transplant.
Meredith C. Foster, ScD, MPH Narittaya Varothai, MD Daniel E. Weiner, MD, MS
In Reply Foster et al make the point that our analysis "should not be used in clinical practice to frame the potential benefits of solidorgan transplant." We agree entirely. It is not an analysis that determines the survival benefit for an individual patient in the current era. Instead, it looks at what has been accomplished in the field of solid-organ transplantation. Excluding less than 1.6% of patients listed for solid-organ transplant, it is an inclusive study that simply follows up with everyone using the Social Security Death Master Files. Our analysis looks at the collective survival benefit of the entire group over 25 years. It is not a study for individual patients and not for clinical use in the current era. Our 2 cohorts comprised listed candidates who did not undergo a transplant and those who did, with approximately 500 000 patients in each cohort. We have 2 options to compare observed survival. We can follow up with patients from a common time point, the time of listing, or we can compare waitlisted patients from the time of listing and transplant recipients from the time of transplant. The second option is deeply flawed because the clinical states of the patients are dramatically different. For example, a potential liver recipient listed at a Model for End-Stage Liver Disease score of 15 is in a dramatically different state of health compared with a liver recipient transplanted at a Model for End-Stage Liver Disease score of 35. We felt that the cleaner analysis would be to follow up with everyone from a common time point.
There are several flaws in this analysis, but it does illustrate the actual fate of everyone listed for solid-organ transplant over 25 years. First, there are the inaccuracies in the Social Security Death Master File and within the United Network for Organ Sharing database itself. Then there is the selection bias of those who actually received a transplant. There is also the immortal person-time bias as pointed out by Foster et al. On the other hand, there is the bias of candidates inappropriately listed for transplant whose condition improves and who are long-term waitlisted survivors.
Foster et al express concern that we dramatically overestimate the survival benefit of solid-organ transplant. This is very unlikely. First, we only report on the benefit observed to date; the actual benefit will only be realized once the entire cohort is exhausted. In the case of kidney transplant, we observe 4.4 years of survival benefit for each recipient-this is actually lower than estimates in the literature. 1 In fact, according to the very article cited by Foster et al, a 20-year sur- 
